Moderna Stock is Soaring. Is It Too Late to Buy?

Moderna reported full-year 2025 revenue of $1.9 billion and a GAAP net loss of $2.8 billion, after peaking at roughly $18 billion in COVID-vaccine revenue in 2022; the stock has risen >70% year-to-date. The company has commercialized RSV and a second COVID vaccine, recently submitted a flu vaccine candidate to regulators aiming for the upcoming season, and is advancing oncology programs including a fully enrolled phase 3 adjuvant melanoma trial (part of eight phase 2/3 trials). Recovery depends on late-stage approvals and commercial launches over multiple years; the analyst view here is constructive but recommends waiting for a dip before buying.

Analysis

The market is compressing Moderna’s multi-year optionality into near-term binary events, concentrating valuation risk into regulatory windows and a few clinical readouts. That creates a short calendar where a single approval or favorable late-stage oncology signal could re-rate the equity materially, while any delay or setback would produce equally sharp downside as investor expectations unwind.

Second-order winners are the compute and CDMO ecosystems that supply rapid-iteration mRNA design and scale manufacturing; increased demand for iterative seasonal vaccines or accelerated oncology trials would disproportionately benefit GPU vendors and contract manufacturers, while incumbent low-cost vaccine producers face margin pressure if premium mRNA SKUs take share. This bifurcation suggests liquidity and gross-margin divergence across the supplier base over the next 6–24 months.

Tail risks are concentrated and measurable: regulatory denial, manufacturing scale issues, or a single negative pivotal oncology readout could reverse sentiment quickly. Conversely, sequenced approvals (seasonal vaccine clearance followed by a positive oncology signal) could produce compounding re-rating over 12–36 months, meaning trade structures should target asymmetric payouts and explicit calendar risk control.

Key Decisions for Investors

• Tactical options play: Buy a 4–6 month call spread on MRNA sized to 0.5–1% of AUM if the stock retraces ≥15% from current levels. Target a 25%/50% OTM call spread (debit <2.5% of notional) to capture a near-term regulatory catalyst; max loss = premium, upside 2–4x if catalyst prints positive.
• Core accumulation on weakness: Build a 2–4% portfolio weight in MRNA on staged purchases between 20–30% below current levels, holding 12–36 months. Rationale: asymmetric upside from successful commercialization of new franchises; principal risk is clinical/regulatory failure—size accordingly and use single-name hedges below key technical levels.
• Fund the biotech optionality with a tech pair: Long NVDA (12–18 months) and short INTC (12–18 months) to express the compute bifurcation that benefits AI-driven drug design. Size net exposure to be cash-neutral versus MRNA buys; expect NVDA to materially outperform if biotech compute demand ramps, but monitor macro-driven repricing risk.
• Protective collar if long MRNA now: Purchase 6–9 month 10% OTM puts and sell 6–9 month 30–40% OTM calls to cap upside for financing protection. This reduces downside volatility ahead of concentrated catalysts while keeping participation in a positive regulatory runway.